ÂÜÀòÂÒÂ×

Dr.Eyal Kalo earned his Ph.D from the Weizmann Institute of Science mastering in the field of cancer research. Eyal completed his studies in 2010 and joined the biotechnology industry where he gained expertisse in leading various R&D projects from concept to launch in the field of medical diagnostics, and natural medicine. Eyal worked as a scientific team leader at the molecular diagnostic division of Beckman Coulter and was responsible for the development of an FDA approved molecular-based diagnostic assay to detect HIV in patients. Prior to that, he served as a senior project manager at IBR Ltd. A company that is under IFF¡¯s structure and develops, manufactures and markets innovative and proprietary natural active ingredients.